Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN D 24 HOUR versus PROMETHACON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN D 24 HOUR versus PROMETHACON.
CLARITIN-D 24 HOUR vs PROMETHACON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism; pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), antiemetic, sedative, and anticholinergic properties. It inhibits central and peripheral H1 receptors, blocks dopamine D2 receptors in the chemoreceptor trigger zone, and has weak alpha-adrenergic blockade.
1 tablet (10 mg loratadine/240 mg pseudoephedrine) orally once daily
25-50 mg intramuscularly or intravenously every 4-6 hours as needed. Maximum intravenous rate: 25 mg/minute. Maximum daily dose: 150 mg.
None Documented
None Documented
Loratadine: 8-11 hours (mean 10.6 ± 4.6 h); desloratadine: 17-24 hours (mean 19.4 ± 7.5 h). Terminal half-life is prolonged in chronic hepatic impairment (mean 37 h for loratadine, 47 h for desloratadine).
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 10-14 hours in hepatic impairment
Renal (40%) as unchanged drug and metabolites; biliary/fecal (minor). Approximately 27% of loratadine and 40% of desloratadine are excreted in urine over 10 days.
Renal (80%) as inactive metabolites, 20% fecal via bile
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine